Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 463

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19

Open access
Fadel, Raef, Morrison, Austin R, Vahia, Amit, Smith, Zachary R, Chaudhry, Zohra, Bhargava, Pallavi, Miller, Joseph, Kenney, Rachel M, Alangaden, George, Ramesh, Mayur S, Henry Ford COVID-19 Management Task Force, Nauriyal, Varidhi, Lakshmikanth, Jayanth, Abdul Hamed, Asif, Nadeem, Owais, Griebe, Kristin, Johnson, Joseph M, Bradley, Patrick, Uduman, Junior, Hegab, Sara, Swiderek, Jennifer, Godfrey, Amanda, Jennings, Jeffrey, Gardner-Gray, Jayna, Ackerman, Adam, Lezotte, Jonathan, Ruhala, Joseph, Samuel, Linoj, Tibbetts, Robert J, Brar, Indira, McKinnon, John, Suleyman, Geehan, Yared, Nicholas, Herc, Erica, Williams, Jonathan, Lanfranco, Odaliz Abreu, Chen, Anne, Zervos, Marcus, Scher, Eric · 2020 · Clinical Infectious Diseases

Abstract

Background: There is no proven antiviral or immunomodulatory therapy for coronavirus disease 2019 (COVID-19). The disease progression associated with the proinflammatory host response prompted us to examine the role of early corticosteroid therapy in patients with moderate to severe COVID-19. Methods: We conducted a single pretest, single posttest quasi-experiment in a multicenter health system in Michigan from 12 March to 27 March 2020. Adult patients with confirmed moderate to severe COVID were included. A protocol was implemented on 20 March 2020 using early, short-course, methylprednisolone 0.5 to 1 mg/kg/day divided in 2 intravenous doses for 3 days. Outcomes of standard of care (SOC) and early corticosteroid groups were evaluated, with a primary composite endpoint of escalation of care from ward to intensive care unit (ICU), new requirement for mechanical ventilation, and mortality. All patients had at least 14 days of follow-up. Results: We analyzed 213 eligible subjects, 81 (38%) and 132 (62%) in SOC and early corticosteroid groups, respectively. The composite endpoint occurred at a significantly lower rate in the early corticosteroid group (34.9% vs 54.3%, P = .005). This treatment effect was observed within each individual component of the composite endpoint. Significant reduction in median hospital length of stay was also observed in the early corticosteroid group (5 vs 8 days, P < .001). Multivariate regression analysis demonstrated an independent reduction in the composite endpoint at 14-days controlling for other factors (adjusted odds ratio: 0.41; 95% confidence interval, .22 – .77). Conclusions: An early short course of methylprednisolone in patients with moderate to severe COVID-19 reduced escalation of care and improved clinical outcomes. Clinical Trials Registration: NCT04374071.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciaa601

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 463

Metadata

Authors
Fadel, R., Morrison, A. R., Vahia, A., Smith, Z. R., Chaudhry, Z., Bhargava, P., Miller, J., Kenney, R. M., Alangaden, G., Ramesh, M. S., Henry Ford COVID-19 Management Task Force, Nauriyal, V., Lakshmikanth, J., Abdul Hamed, A., Nadeem, O., Griebe, K., Johnson, J. M., Bradley, P., Uduman, J., Hegab, S., Swiderek, J., Godfrey, A., Jennings, J., Gardner-Gray, J., Ackerman, A., Lezotte, J., Ruhala, J., Samuel, L., Tibbetts, R. J., Brar, I., McKinnon, J., Suleyman, G., Yared, N., Herc, E., Williams, J., Lanfranco, O. A., Chen, A., Zervos, M., & Scher, E.
Venue
Clinical Infectious Diseases
Published
2020-05-19
Volume
71
Issue
16
Pages
2114-2120
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W3024848265
Cited by
463
References
28
FWCI
13.10
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.